Latest Pharma and Biotech News
Pharmaceutical
26 March 2025 The Chinese government is contemplating a new drug reimbursement category called category C to make commercial insurance companies a major payer. If the new category is introduced, it is expected to significantly accelerate China’s innovation, said speakers at the BIOCHINA event held in Suzhou.
Today's issue
Refine Search
Pharmaceutical
German drugmaker Bayer has signed a global licensing agreement with China-based Puhe BioPharma, gaining exclusive rights to develop and commercialize an early-stage precision oncology therapy targeting MTAP-deleted tumors. 27 March 2025
Biotechnology
French biotech company Transgene has reported its 2024 financial results and provided updates on its cancer immunotherapy pipeline. 27 March 2025
Biotechnology
Danish cancer specialist Genmab today announced that the Japanese Ministry of Health, Labor and Welfare has approved Tivdak (tisotumab vedotin) for the treatment of advanced or recurrent cervical cancer that has progressed on or after cancer chemotherapy. 27 March 2025
Biotechnology
Cambridge, USA-based RNS specialist Wave Life Sciences has announced positive data from the Phase II FORWARD-53 trial of WVE-N531, which is an exon skipping oligonucleotide being investigated in boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 53 skipping. 27 March 2025
Pharmaceutical
There has been talk of the job cuts impacting US health agencies for weeks. 27 March 2025
Pharmaceutical
Genetic diseases company BridgeBio Pharma has announced that the Japanese Ministry of Health, Labor and Welfare has approved acoramidis, under the brand name Beyonttra, for the treatment of adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). 27 March 2025
Pharmaceutical
UK-based specialty pharma Kelso Pharma, which is backed by private equity investor Apposite Capital, announced that it has secured over £140 million ($180 million) of acquisition funding. 27 March 2025
Biotechnology
US biotech Equillium reported Thursday that its lead drug candidate itolizumab failed to meet the main objective in a Phase III trial for patients with acute graft-versus-host disease, sending shares tumbling in pre-market trading. 27 March 2025
Pharmaceutical
The US Senate has confirmed President Donald Trump’s nominees to lead two of the country’s top health agencies, approving surgeon Marty Makary as Commissioner of the Food and Drug Administration and economist and physician Jay Bhattacharya as director of the National Institutes of Health. 27 March 2025
Biotechnology
Swiss ophthalmic drug company Alcon today announced it has acquired a majority interest in Aurion Biotech, a privately-held US clinical-stage company developing advanced cell therapies to treat eye diseases. 27 March 2025
Biotechnology
San Francisco-based epigenetic editing company Epicrispr Biotechnologies has secured $68 million in the first close of its Series B financing. 27 March 2025
Generics
German family-owned pain specialist Grünenthal today published its 2024 financial results, marking a year of impressive resilience, strategic growth and operational excellence. 27 March 2025
Biotechnology
Johnson & Johnson has announced important overall survival (OS) results from the Phase III MARIPOSA study. 27 March 2025
Biotechnology
The US Biotechnology Innovation Organization (BIO) has released results from a membership survey that underscores the significant, global integration of the biomedical supply chain. 27 March 2025
Pharmaceutical
The Trump administration plans to pull US funding from Gavi, the global vaccine alliance that helps deliver immunizations to children in lower-income countries, according to internal documents obtained by the New York Times. 26 March 2025
Pharmaceutical
US biotech Exelixis has secured a sixth indication for its cancer drug Cabometyx (cabozantinib), following a green light from the Food and Drug Administration for advanced neuroendocrine tumors (NET). 26 March 2025
Pharmaceutical
The Global Trends in R&D 2025 report from contract research organization IQVIA has landed. 26 March 2025
Pharmaceutical
French independent pharma major Servier is ramping up its industrial development with the inauguration of a new production unit for the active ingredient of one of its venous medicines. 26 March 2025
Pharmaceutical
The Chinese government is contemplating a new drug reimbursement category called category C to make commercial insurance companies a major payer. If the new category is introduced, it is expected to significantly accelerate China’s innovation, said speakers at the BIOCHINA event held in Suzhou. 26 March 2025
All news
Pharmaceutical
German drugmaker Bayer has signed a global licensing agreement with China-based Puhe BioPharma, gaining exclusive rights to develop and commercialize an early-stage precision oncology therapy targeting MTAP-deleted tumors. 27 March 2025
Biotechnology
French biotech company Transgene has reported its 2024 financial results and provided updates on its cancer immunotherapy pipeline. 27 March 2025
Biotechnology
Danish cancer specialist Genmab today announced that the Japanese Ministry of Health, Labor and Welfare has approved Tivdak (tisotumab vedotin) for the treatment of advanced or recurrent cervical cancer that has progressed on or after cancer chemotherapy. 27 March 2025
Biotechnology
Cambridge, USA-based RNS specialist Wave Life Sciences has announced positive data from the Phase II FORWARD-53 trial of WVE-N531, which is an exon skipping oligonucleotide being investigated in boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 53 skipping. 27 March 2025
Pharmaceutical
There has been talk of the job cuts impacting US health agencies for weeks. 27 March 2025
Pharmaceutical
Genetic diseases company BridgeBio Pharma has announced that the Japanese Ministry of Health, Labor and Welfare has approved acoramidis, under the brand name Beyonttra, for the treatment of adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). 27 March 2025
Pharmaceutical
UK-based specialty pharma Kelso Pharma, which is backed by private equity investor Apposite Capital, announced that it has secured over £140 million ($180 million) of acquisition funding. 27 March 2025
Biotechnology
US biotech Equillium reported Thursday that its lead drug candidate itolizumab failed to meet the main objective in a Phase III trial for patients with acute graft-versus-host disease, sending shares tumbling in pre-market trading. 27 March 2025
Pharmaceutical
The US Senate has confirmed President Donald Trump’s nominees to lead two of the country’s top health agencies, approving surgeon Marty Makary as Commissioner of the Food and Drug Administration and economist and physician Jay Bhattacharya as director of the National Institutes of Health. 27 March 2025
Biotechnology
Swiss ophthalmic drug company Alcon today announced it has acquired a majority interest in Aurion Biotech, a privately-held US clinical-stage company developing advanced cell therapies to treat eye diseases. 27 March 2025
Biotechnology
San Francisco-based epigenetic editing company Epicrispr Biotechnologies has secured $68 million in the first close of its Series B financing. 27 March 2025
Generics
German family-owned pain specialist Grünenthal today published its 2024 financial results, marking a year of impressive resilience, strategic growth and operational excellence. 27 March 2025
Biotechnology
Johnson & Johnson has announced important overall survival (OS) results from the Phase III MARIPOSA study. 27 March 2025
Biotechnology
The US Biotechnology Innovation Organization (BIO) has released results from a membership survey that underscores the significant, global integration of the biomedical supply chain. 27 March 2025
Pharmaceutical
The Trump administration plans to pull US funding from Gavi, the global vaccine alliance that helps deliver immunizations to children in lower-income countries, according to internal documents obtained by the New York Times. 26 March 2025
Pharmaceutical
US biotech Exelixis has secured a sixth indication for its cancer drug Cabometyx (cabozantinib), following a green light from the Food and Drug Administration for advanced neuroendocrine tumors (NET). 26 March 2025
Pharmaceutical
The Global Trends in R&D 2025 report from contract research organization IQVIA has landed. 26 March 2025
Pharmaceutical
French independent pharma major Servier is ramping up its industrial development with the inauguration of a new production unit for the active ingredient of one of its venous medicines. 26 March 2025
Pharmaceutical
The Chinese government is contemplating a new drug reimbursement category called category C to make commercial insurance companies a major payer. If the new category is introduced, it is expected to significantly accelerate China’s innovation, said speakers at the BIOCHINA event held in Suzhou. 26 March 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze